Streetbeat News

ARTV

Artiva Biotherapeutics Inc

Industry

Research and Development in Biotechnology (except Nanobiotechnology)

Open

11.06

Mkt cap

272M

Volume

36K

High

11.85

P/E Ratio

-4.52

52-wk high

17.31

Low

10.79

Div yield

N/A

52-wk low

9.68

Trading halt status for ARTV was updated at 10:10:00 AM ET. The IPO security has been released for quotation.

Portfolio Pulse from Benzinga Newsdesk

July 19, 2024 | 2:10 pm

Artiva Biotherapeutics has priced its upsized $167 million initial public offering (IPO) of 13.92 million common shares at $12 per share. The shares will begin trading on the Nasdaq Global Market under the symbol 'ARTV' on July 19, 2024, with the offering expected to close on July 22, 2024, pending customary closing conditions.

Portfolio Pulse from Benzinga Newsdesk

July 19, 2024 | 6:27 am

Artiva Biotherapeutics, Inc (NASDAQ:ARTV) is set to start trading on the NASDAQ exchange on July 19. The IPO price is expected to be between $14.00 and $16.00 per share, with an insider lock-up period of 180 days ending on January 15, 2025. Artiva is a clinical-stage biotechnology company focused on NK cell-based therapies for autoimmune diseases and cancers.

Portfolio Pulse from Benzinga Insights

July 18, 2024 | 3:00 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.